Meeting
2016 ASCO Annual Meeting
FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – accord 21 (METHEP-2), a unicancer GI trial.
Authors
Marc Ychou
Montpellier Cancer Institute, Montpellier, France
Marc Ychou , Michel Rivoire , Simon Thezenas , Rosine Guimbaud , Francois Ghiringhelli , Anne Mercier-Blas , Laurent Mineur , Eric Francois , Faiza Khemissa , Driffa Moussata , Yves Becouarn , Philippe Houyau , Thomas Aparicio , Rene Adam , Marie-Pierre Galais , Franck Audemar , Eric Assenat , Trevor Stanbury , Olivier Bouche
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
2009-012813-22
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3512)
DOI
10.1200/JCO.2016.34.15_suppl.3512
Abstract #
3512
Poster Bd #
209
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A randomized phase II study of perioperative chemotherapy plus bevacizumab versus postoperative chemotherapy plus bevacizumab inpatients with upfront resectable hepatic colorectal metastases (APPROACH).
First Author: You Jin Chun
Poster
2018 ASCO Annual Meeting
Outcomes of oxaliplatin-based (Ox) chemotherapy (CT) on R0 resection of colonic liver metastases (CLM).
First Author: Nicholas Adam Bosma
Poster
2013 ASCO Annual Meeting
Cetuximab and chemotherapy in the treatment of patients with initially “nonresectable” colorectal (CRC) liver metastases: Long-term follow-up of the CELIM trial.
First Author: Gunnar Folprecht
Poster
2012 ASCO Annual Meeting
Triplet chemotherapy (TC) with FOLFIRINOX regimen in metastatic colorectal cancer (mCRC): Experience of the Val d'Aurelle Center.
First Author: Emmanuelle Samalin